Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
07/2003
07/10/2003WO2003055911A2 Cystine-knot fold protein
07/10/2003WO2003055910A1 Beta-amyloid binding factors and inhibitors thereof
07/10/2003WO2003055884A1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
07/10/2003WO2003055882A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors
07/10/2003WO2003055880A2 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
07/10/2003WO2003055879A2 Tropane derivative, chelation product comprising this tropane derivative and a metal or a metal complex, and radiopharmaceutical
07/10/2003WO2003055877A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
07/10/2003WO2003055875A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055874A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055873A1 Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
07/10/2003WO2003055871A1 DECAHYDRONAPHTHO[2,3-c]FURAN DERIVATIVES
07/10/2003WO2003055868A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors
07/10/2003WO2003055865A1 Quinazolinone derivative
07/10/2003WO2003055863A1 Novel alkansulfonamides as endothelin antagonists
07/10/2003WO2003055848A2 Urea derivatives as vr1- antagonists
07/10/2003WO2003055521A1 Remedies for mild recognition deflict
07/10/2003WO2003055501A1 The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
07/10/2003WO2003055495A1 ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17β-ESTRADIOL-3-LOWER ALKANOATE, METHOD OF ADMINISTERING THE SAME AND PROCESS OF PREPARATION
07/10/2003WO2003055492A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
07/10/2003WO2003055487A1 METHOD OF CONTROLLING DAMAGE MEDIATED BY α, β- UNSATURATED ALDEHYDES
07/10/2003WO2003055486A1 A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity
07/10/2003WO2003055485A1 Dosing regimen for ppar-gamma activators
07/10/2003WO2003055484A1 Urea derivatives
07/10/2003WO2003055479A1 Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
07/10/2003WO2003055478A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
07/10/2003WO2003055456A1 Stable surfactant compositions for suspending components
07/10/2003WO2003055440A2 Compositions and methods for the treatement of immune related diseases
07/10/2003WO2003055438A2 Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
07/10/2003WO2003055424A1 METHOD OF SYSTEMICALLY DELIVERING SSRIs
07/10/2003WO2003055335A1 Modified methionine rich food products and process for their manufacture
07/10/2003WO2003050119A3 Urea substituted imidazopyridines
07/10/2003WO2003043987A3 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
07/10/2003WO2003020289A9 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
07/10/2003WO2003011227A3 Taste masking composition
07/10/2003WO2003008452A3 Bispecific monoclonal antibodies to il-12 and il-18 receptors
07/10/2003WO2003007880A3 Inhibition of behab cleavage and primary central nervous system (cns) tumors
07/10/2003WO2003006440A8 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
07/10/2003WO2003004511A3 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
07/10/2003WO2003002175A8 Enhanced systemic absorption of intradermally delivered substances
07/10/2003WO2002102412A3 Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
07/10/2003WO2002101392A3 Methods for treating disorders of the nervous and reproductive systems
07/10/2003WO2002100354A8 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
07/10/2003WO2002096937A3 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
07/10/2003WO2002096368A3 Encapsulation of nanosuspensions in liposomes and microspheres
07/10/2003WO2002074956A3 Dopaminergic neuronal survival-promoting factors and uses thereof
07/10/2003WO2002063008A3 Intracellular signaling molecules
07/10/2003WO2002059267A3 Constitutively desensitized g protein-coupled receptors
07/10/2003WO2002046409A3 Proteins and nucleic acids encoding same
07/10/2003WO2002018581A3 G-protein coupled receptors
07/10/2003WO2002009675A9 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
07/10/2003WO2002005813A3 Method for preventing and/or decreasing amyloid production with polycyclic compounds
07/10/2003WO2001089550A3 Use of ciliary neurotrophic factor
07/10/2003US20030131370 Disruption of the glutathione S-transferase-Omega-1 gene
07/10/2003US20030130523 Delivers more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood; substituted phenylacetanilides containing carboxyl group(s)
07/10/2003US20030130515 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
07/10/2003US20030130513 Useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from tobacco or nicotine.
07/10/2003US20030130508 3,5-bis(trifluoromethyl)phenylmethylene-substituted derivatives of nicotamide or pyridinylaminocarbonyl compounds; used to treat disorders of the central nervous system such as anxiety, depression and psychosis.
07/10/2003US20030130504 Antidepressants
07/10/2003US20030130495 G-protein coupled receptors, signal transduction pathways
07/10/2003US20030130357 Inhibiting ornithine decarboxylase (involved with production of putrescine) with N(1),N(11)-diethylnorspermine
07/10/2003US20030130354 Such as 3,5-dimethyl-1-adamantanecarboximidamide hydrochloride; glutamate receptors; methyl-D-aspartate receptors; neurodegenerative diseases; side effect reduction
07/10/2003US20030130353 Administering dual serotonin norepinephrine reuptake inhibitor
07/10/2003US20030130352 Such as 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E for treatment of cystic fibrosis
07/10/2003US20030130350 Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
07/10/2003US20030130339 Such as (E)-2-pyridineethenyl-4-fluorobenzyl sulfone; antitumor/anticancer agents
07/10/2003US20030130337 Indole derivatives as anti-inflammatory agents
07/10/2003US20030130335 Protein tyrosine phosphatases inhibitors
07/10/2003US20030130333 Combination product and methods of use
07/10/2003US20030130325 Substituted tryptophan derivatives
07/10/2003US20030130322 Biaryl ether derivative as opiod antagonist
07/10/2003US20030130314 Administering 4-amido-piperidineo derivatives to patients already under the background influence of an opioid agonist
07/10/2003US20030130309 Antiinflammatory agents; rheumatic diseases
07/10/2003US20030130305 Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
07/10/2003US20030130303 Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
07/10/2003US20030130297 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
07/10/2003US20030130295 Substituted 2-aminoacetamides and the use thereof
07/10/2003US20030130292 Immunosuppressants; autoimmune disease; skin disorders; Crohn's disease; antidiabetic agents; anticancer agents; antiarthritic agents
07/10/2003US20030130291 Dissolving in solvents; precipitation; isolation; sleep disorders
07/10/2003US20030130289 Inhibitors of glycogen synthase kinase 3
07/10/2003US20030130287 Psychological disorders; central nervous system disorders; antidepressants; Parkinson's disease; Alzheimer's disease;cardiovascular disorders
07/10/2003US20030130286 Antiproliferative agents; anticancer agents; central nervous system disorders; antiarthritic agents
07/10/2003US20030130283 CRF receptor antagonists and methods relating thereto
07/10/2003US20030130282 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
07/10/2003US20030130279 Hyperglycemic agents; dietetics; cardiovascular disorders; immunology modulation; osteoporosis; cognition activators
07/10/2003US20030130277 Pyrazoloquinolinone derivatives as protein kinase C inhibitors
07/10/2003US20030130273 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
07/10/2003US20030130267 Midazolane maleate in water, alcohol solution
07/10/2003US20030130261 Central nervous system disorders; psychological disorders; inflammatory bowel disorders
07/10/2003US20030130260 Aryl fused azapolycyclic compounds
07/10/2003US20030130256 Stimulant of central nervous system regeneration
07/10/2003US20030130254 Respiratory system disorders; antihistamines; antiarthritic agents
07/10/2003US20030130252 Process for affecting neurologic progression
07/10/2003US20030130251 Blocking amyloid deposits; Alzheimer's disease, Down syndrome
07/10/2003US20030130244 Mixture of estrogen, androgen and anticholinergic agent
07/10/2003US20030130238 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
07/10/2003US20030130236 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
07/10/2003US20030130235 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
07/10/2003US20030130203 Sleep disorders
07/10/2003US20030130201 Mixture with ascorbic acid, proline and lysine
07/10/2003US20030130182 Secreted and transmembrane polypeptides and nucleic acids encoding the same
1 ... 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 ... 1833